Time to Buy Pfizer (PFE) or Metsera (MTSR) Stock?

Pfizer announced its acquisition of biotechnology firm Metsera for $4.9 billion, with potential milestone payments increasing the deal to $7.3 billion, a strategic move to re-enter the booming $100 billion obesity drug market. This acquisition, funded by cash and debt while maintaining Pfizer's dividend, aims to leverage Metsera's clinical-stage GLP-1 pipeline to compete with market leaders like Eli Lilly and Novo Nordisk, and to mitigate revenue loss from upcoming patent expirations. While Metsera's stock surged over 60% post-announcement, Pfizer's shares remained flat, as the company navigates a period of modest projected sales and EPS growth following the decline in COVID-19 product demand.

Analysis

Pfizer's planned acquisition of Metsera for $4.9 billion, with a potential value up to $7.3 billion, is a strategic re-entry into the lucrative obesity drug market, estimated to reach $100 billion by 2030. This move follows Pfizer's previous discontinuation of its own candidate, danuglipron, and aims to address looming patent expirations for key drugs like Eliquis and Ibrance. Metsera, a clinical-stage firm with no near-term revenue prospects, brings a pipeline of GLP-1 candidates, including MET-097i (Phase 2) and MET-233i (Phase 1), with the latter showing a promising 8.4% body weight loss in its first five weeks. Despite this strategic pivot, Pfizer's financial outlook remains muted, with sales projected to be flat in FY25 and decline 1% in FY26, alongside a forecasted 2% dip in FY26 EPS. The market's reaction has been telling: Metsera's stock (MTSR) surged over 60% to trade above the initial $47.50 per share offer, while Pfizer's (PFE) shares remained flat. Pfizer intends to fund the deal with cash and debt, maintaining its dividend, which currently yields over 7% on a low forward P/E multiple of 7x. However, Metsera's own earnings trajectory is weakening, with projected losses widening in FY26, contributing to its Zacks Rank #4 (Sell).

Key Decisions for Investors

• For Pfizer (PFE) investors, this acquisition should be viewed as a long-term strategic play to secure a position in the obesity market, not a near-term growth catalyst; the stock's low valuation and high dividend yield may appeal to value-oriented portfolios willing to tolerate a flat revenue outlook and clinical trial risks.
• Investors holding Metsera (MTSR) should consider the significant run-up in its stock price, which has already surpassed the initial cash offer of $47.50, and evaluate the risk-reward of holding for potential milestone payments versus locking in current gains, given the inherent clinical and regulatory uncertainties of its pipeline.
• The transaction validates the high strategic value of GLP-1 assets but does not pose an immediate threat to the market dominance of Eli Lilly and Novo Nordisk, as Metsera's products are several years from potential commercialization.